N-(2-羟基-1,1-二甲基乙基)-2,6-二氟苯甲酰胺 | 150079-31-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(2-羟基-1,1-二甲基乙基)-2,6-二氟苯甲酰胺
• 英文名称: 2,6-difluoro-N-(1-hydroxy-2-methylpropan-2-yl)benzamide
• 英文别名: N-(2-hydroxy-1,1-dimethylethyl)-2,6-difluorobenzamide；N-(1,1-dimethyl-2-hydroxyethyl)-2,6-difluorobenzamide；2,6-difluoro-N-(2-hydroxy-1,1-dimethyl-ethyl)-benzamide
• CAS: 150079-31-5
• 化学式: C₁₁H₁₃F₂NO₂
• mdl: MFCD12180039
• 分子量: 229.227
• InChiKey: QWCOVJAVTCLFPO-UHFFFAOYSA-N

物化性质

• 沸点：
  320.1±42.0 °C(Predicted)
• 密度：
  1.237±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(2-羟基-1,1-二甲基乙基)-2,6-二氟苯甲酰胺 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成 2-(2,6-二氟苯基)-4,4-二甲基-5H-1,3-间唑
  参考文献：
  名称：

  [EN] DEUTERATED COMPOUNDS AS IMMUNOMODULATORS
  [FR] COMPOSÉS DEUTÉRÉS UTILISÉS COMME IMMUNOMODULATEURS

  摘要：

  本发明提供了用于调节C5a受体的化合物。这些化合物具有以下式（I），包括立体异构体和其药学上可接受的盐，其中R1、R2和R3如本文所定义。还公开了与制备和使用这些化合物相关的方法，以及包含这些化合物的药物组合物。

  公开号：

  WO2019089468A1
• 作为产物：
  描述：

  2-氨基-2-甲基-1-丙醇 、 2,6-二氟苯甲酰氯 在 氮 、 二氯甲烷 、 magnesium sulfate 、 hexanes 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 16.0h， 以afforded 12.05 g (93%) of the amide的产率得到N-(2-羟基-1,1-二甲基乙基)-2,6-二氟苯甲酰胺
  参考文献：
  名称：

  Inhibitors of cytosolic phospholipase A2

  摘要：

  本发明提供了化学抑制剂，用于抑制各种磷脂酶酶活性，特别是胞质磷脂酶A2酶（cPLA2），更具体地包括胞质磷脂酶A2α酶（cPLA2α）的抑制剂。在某些实施例中，抑制剂具有公式I：其中组成变量如本文所定义。

  公开号：

  US07557135B2

文献信息

• Fungicides for the control of take-all disease of plants
  申请人：Monsanto Company

  公开号：US20010046975A1

  公开（公告）日：2001-11-29

  A method of controlling Take-all disease of plants by applying, preferably to the seed prior to planting, a fungicide of the formula 1 wherein Z 1 and Z 2 are C or N and are part of an aromatic ring selected from benzene, pyridine, thiophene, furan, pyrrole, pyrazole, thiazole, and isothiazole; A is selected from —C(X)-amine, —C(O)—SR 3 , —NH—C(X)R 4 , and —C(═NR )—XR 7 ; B is —W m —Q(R 2 ) 3 or selected from o-tolyl, 1-naphthyl, 2-naphthyl, and 9-phenanthryl, each optionally substituted with halogen or R 4 ; Q is C, Si, Ge, or Sn; W is —C(R 3 ) p H (2-p) —; or when Q is C, W is selected from —C(R 3 ) p H (2-p) —, —N(R 3 ) m H (1-m) —, —S(O) p —, and —O—; X is O or S; n is 0, 1, 2, or 3; m is 0 or 1; p is 0, 1, or 2; each R is independently selected from a) halo, formyl, cyano, amino, nitro, thiocyanato, isothiocyanato, trimethylsilyl, and hydroxy; b) C1-C4 alkyl, alkenyl, alkynyl, C3-C6 cycloalkyl, and cycloalkenyl, each optionally substituted with halo, hydroxy, thio, amino, nitro, cyano, formyl, phenyl, C1-C4 alkoxy, alkylcarbonyl, alkylthio, alkylamino, dialkylamino, alkoxycarbonyl, (alkylthio)carbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylsulfinyl, or alkylsulfonyl; c) phenyl, furyl, thienyl, pyrrolyl, each optionally substituted with halo, formyl, cyano, amino, nitro, C1-C4 alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, dialkylamino, haloalkyl, and haloalkenyl; d) C1-C4 alkoxy, alkenoxy, alkynoxy, C3-C6 cycloalkyloxy, cycloalkenyloxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino, alkylcarbonylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonyl, alkylcarbonyloxy, alkoxycarbonyl, (alkylthio)carbonyl, phenylcarbonylamino, phenylamino, each optionally substituted with halo; wherein two R groups may be combined to form a fused ring; each R 2 is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and phenyl, each optionally substituted with R 4 or halogen; and wherein, when Q is C, R 2 may also be selected from halo, alkoxy, alkylthio, alkylamino, and dialkylamino; wherein two R 2 groups may be combined to form a cyclo group with Q; R 3 is C1-C4 alkyl; R 4 is C1-C4 alkyl, haloalkyl, alkoxy, alkylthio, alkylamino, or dialkylamino; and R 7 is C1-C4 alkyl, haloalkyl, or phenyl, optionally substituted with halo, nitro, or R 4 ; or an agronomic salt thereof.

  通过在种子播种前，优选地向种子施用公式1的杀菌剂来控制植物的扁腐病，其中Z1和Z2是C或N，是从苯，吡啶，噻吩，呋喃，吡咯，吡唑，噻唑和异噻唑中选择的芳香环的一部分；A是从—C（X）-胺，—C（O）—SR3，—NH—C（X）R4和—C（═NR）—XR7中选择的；B是—Wm—Q（R2）3或从o-甲苯基，1-萘基，2-萘基和9-菲基中选择的，每个都可以用卤素或R4取代；Q是C，Si，Ge或Sn；W是—C（R3）pH（2-p）—；或当Q是C时，W从—C（R3）pH（2-p）—，—N（R3）mH（1-m）—，—S（O）p—和—O—中选择；X是O或S；n是0，1，2或3；m是0或1；p是0，1或2；每个R是独立选择的，从a）卤素，酰基，氰基，氨基，硝基，硫氰酸基，异硫氰酸基，三甲基硅基和羟基中选择；b）C1-C4烷基，烯基，炔基，C3-C6环烷基和环烯基，每个都可以用卤素，羟基，硫，氨基，硝基，氰基，酰基，苯基，C1-C4烷氧基，烷基羰基，烷基硫基，烷基氨基，二烷基氨基，烷氧羰基，（烷硫）羰基，烷基氨基羰基，二烷基氨基羰基，烷基亚砜基或烷基磺酰基取代；c）苯基，呋喃基，噻吩基，吡咯基，每个都可以用卤素，酰基，氰基，氨基，硝基，C1-C4烷基，烯基，炔基，烷氧基，烷基硫基，烷基氨基，二烷基氨基，卤代烷基和卤代烯基取代；d）C1-C4烷氧基，烯氧基，炔氧基，C3-C6环烷氧基，环烯氧基，烷基硫基，烷基亚砜基，烷基磺酰基，烷基氨基，二烷基氨基，烷基羰基氨基，氨基羰基，烷基氨基羰基，二烷基氨基羰基，烷基羰基，烷基羰氧基，烷氧羰基，（烷硫）羰基，苯基羰基氨基，苯基氨基，每个都可以用卤素取代；其中两个R基可以结合形成融合环；每个R2是独立选择的，从烷基，烯基，炔基，环烷基，环烯基和苯基中选择，每个都可以用R4或卤素取代；当Q为C时，R2还可以选择自卤素，烷氧基，烷基硫基，烷基氨基和二烷基氨基；其中两个R2基可以结合形成带有Q的环；R3是C1-C4烷基；R4是C1-C4烷基，卤代烷基，烷氧基，烷基硫基，烷基氨基或二烷基氨基；R7是C1-C4烷基，卤代烷基或苯基，可以选择自卤素，硝基或R4取代；或其农学盐。
• Amide derivative
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：US20020147204A1

  公开（公告）日：2002-10-10

  A compound of the formula: 1 wherein Ar is optionally substituted phenyl, etc.; n is 0, 1 or 2; R 1 is hydogen atom, optionally substituted alkyl, etc.; R 2 and R 3 are independently optionally substituted alkyl, etc.; R 4 and R 5 are independently hydrogen atom or optionally substituted alkyl; R 6 is hydrogen atom, hydroxy or alkyl; or a pharmaceutically acceptable salt thereof is useful as a medicament for treating retinal degenerative disorders and the like.

  公式1的化合物：其中Ar是可选取代的苯基等；n为0、1或2；R1为氢原子、可选取代的烷基等；R2和R3分别为可选取代的烷基等；R4和R5分别为氢原子或可选取代的烷基；R6为氢原子、羟基或烷基；或其药学上可接受的盐，用于治疗视网膜退行性疾病等。
• Derivatives of n-(1h-indazolyl)-and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for treatment of pain
  申请人：Fletcher Robert Stephen

  公开号：US20070078156A1

  公开（公告）日：2007-04-05

  Compounds of formula (I): wherein A, B and D are each C, N, O or S; E is C or N; the dotted circle within the five-membered ring indicates that the ring may be unsaturated or partially saturated; R 1 is halogen, hydroxy, C 1-6 alkyl, haloC 1-6 alkyl, hydroxyC 1-6 alkyl, C 1-6 alkoxy, halo C 1-6 alkoxy, hydroxyC 1-6 alkoxy, C 3-7 cycloalkyl, C 3-5 cycloalkylC 1-4 alkyl, NR 7 R 8 , C 1-6 alkyl substituted with NR 7 R 8 , C, 1-6 alkoxy substituted with NR 7 R 8 , oxo, cyano, SO 2 NR 7 R 8 , CONR 7 R 8 , NHCOR 9 or NHSO 2 R 9 ; R 2 is halogen, hydroxy, C 1-6 alkyl, halo C 1-6 alkyl, hydroxyC 1-6 alkyl, C 1-6 alkoxy, halo C 1-6 alkoxy, hydroxyC 1-6 alkoxy, C 3-7 cycloalkyl, C 3-5 cycloalkylC 1-4 alkyl, NR 7 R 8 , C 1-6 alkyl substituted with NR 7 R 8 , C 1-6 , alkoxy substituted with NR 7 R 8 , cyano, SON 2 R 7 R 8 , CONR 7 R 8 , NHCOR 9 , or NHSO 2 R 9 ; R 3 and R 4 are each independently hydrogen, C 1-6 , alkyl, phenyl or halophenyl; R 5 and R 6 are, at each occurrence, independently hydrogen, C 1-6 alkyl, phenyl, halophenyl or carboxy; X is an oxygen or sulfur atom; Y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; n is either zero or an integer from 1 to 3; p is either zero or an integer from, 1 to 4; and q is either zero or an integer from 1 to 3; the other substituents are defined in claim 1; are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1).

  式(I)的化合物：其中A、B和D分别为C、N、O或S；E为C或N；五元环内的点圈表示该环可能不饱和或部分饱和；R1为卤素、羟基、C1-6烷基、卤代C1-6烷基、羟基C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基、羟基C1-6烷氧基、C3-7环烷基、C3-5环烷基C1-4烷基、NR7R8、C1-6烷基取代的NR7R8、C1-6烷氧基取代的NR7R8、氧代、氰基、SO2NR7R8、CONR7R8、NHCOR9或NHSO2R9；R2为卤素、羟基、C1-6烷基、卤代C1-6烷基、羟基C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基、羟基C1-6烷氧基、C3-7环烷基、C3-5环烷基C1-4烷基、NR7R8、C1-6烷基取代的NR7R8、C1-6烷氧基取代的NR7R8、氰基、SON2R7R8、CONR7R8、NHCOR9或NHSO2R9；R3和R4分别独立地为氢、C1-6烷基、苯基或卤代苯基；R5和R6在每次出现时独立地为氢、C1-6烷基、苯基、卤代苯基或羧基；X为氧或硫原子；Y为芳基、杂芳基、碳环基或融合碳环基基团；n为零或1至3的整数；p为零或1至4的整数；q为零或1至3的整数；其他取代基在权利要求中定义；在治疗疼痛和其他通过调节vanilloid-1受体（VR1）功能改善的疾病中特别有用的治疗化合物。
• Inhibitors of Cytosolic Phospholipase A2
  申请人：McKew John C.

  公开号：US20100022536A1

  公开（公告）日：2010-01-28

  This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A 2 enzymes (cPLA 2 ), more particularly including inhibitors of cytosolic phospholipase A 2 alpha enzymes (cPLA 2 α). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.

  该发明提供了化学抑制剂，用于抑制各种磷脂酶酶的活性，特别是细胞质磷脂酶A2酶（cPLA2），更特别地包括细胞质磷脂酶A2α酶（cPLA2α）的抑制剂。在某些实施例中，抑制剂具有公式I：其中组分变量如此处所定义。
• Inhibitors of benzylaminoxidases, selective with respect to other aminoxidases
  申请人：CONSIGLIO NAZIONALE DELLE RICERCHE

  公开号：EP0210140A2

  公开（公告）日：1987-01-28

  Selective inhibitors of benzylaminoxidases, said inhibitors consisting of compounds of the general formula I wherein X is a group C-R4 or a nitrogen atom, R' and R2, which can be the same or different from each other, represent hydrogen, hydroxyl groups, alkoxyl groups, or alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, hydroxyalkoxyalkyl, hydroxyalkoxyl, alkoxyalkoxyl, hydroxyalkoxyalkxyl, phenoxyl or phenoxyalkyl groups or their substitution derivatives in the phenxyl group, provided that no more than one of the same be hydrogen, and one or more of the symbols R3, R4 or R5 are hydrogen atoms or alkyl or hydroxyl or alkoxyl or hydroxyalkyl or hydroxyalkoxyl or hydroxyalkoxyalkyl or haloalkyl or carboxylic or carboxylic or ester or amido or nitrile or sulfonic groups or halogen atoms or nitro groups.

  苄基氨基氧化酶的选择性抑制剂，所述抑制剂由通式 I 的化合物组成 其中 X 是基团 C-R4 或氮原子，R'和 R2 可以相同或不同，代表氢、羟基、烷氧基或烷基、烯基、羟烷基、烷氧基烷基、羟基烷氧基、羟基烷氧基、烷氧基烷氧基、羟基烷氧基烷氧基、苯氧基或苯氧基烷基或它们在苯氧基中的取代衍生物、只要其中不超过一个为氢，且一个或多个符号 R3、R4 或 R5 为氢原子或烷基或羟基或烷氧基或羟基烷基或羟基烷氧基或羟基烷氧基或卤代烷基或羧基或羧酸基或酯基或氨基或腈基或磺酸基或卤原子或硝基。